Visceral leishmaniasis: Advancements in vaccine development via classical and molecular approaches

Frontiers in Immunology

Volumn 5, Issue AUG, 2014, Pages

  Joshi, Sumit ^a   Rawat, Keerti ^a   Yadav, Narendra Kumar ^a   Kumar, Vikash ^a   Siddiqi, Mohammad Imran ^a   Dube, Anuradha ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

DNA vaccines; Mutant vaccines; Recombinant vaccines; Synthetic peptide vaccines; Visceral leishmaniasis

Indexed keywords

A2 PROTEIN; ANTIGEN; BCG VACCINE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN 63; HETEROLOGOUS PRIME BOOST VACCINE; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; KINETOPLASTID MEMBRANE PROTEIN 11; KMP 11; LEISHMANIA VACCINE; LIVE VACCINE; PARASITE ANTIGEN; PEPTIDE VACCINE; POLYPROTEIN VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SALIVARY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

DRUG DEVELOPMENT; HUMAN; LIPOSOMAL DELIVERY; MUTANT; NONHUMAN; PROTEOMICS; PSYCHODIDAE; REVIEW; VACCINE PRODUCTION; VISCERAL LEISHMANIASIS;

EID: 84930476625     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00380     Document Type: Review

References (128)

1. Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 5:873-82. doi: 10.1038/nrmicro1748
2. Hasker E, Singh SP, Malaviya P, Picado A, Gidwani K, Singh RP, et al. Visceral leishmaniasis in rural Bihar, India. Emerg Infect Dis (2012) 18(10):1662-4. doi:10.3201/eid1810.111083
3. Desjeux P. Leishmaniasis. Nat Rev Microbiol (2004) 2:692-3. doi:10.1038/nrmicro981
4. Piscopo T, Azzopardi M. Leishmaniasis. Postgrad Med J (2006) 83:649-57. doi:10.1136/pgmj.2006.047340corr1
5. Lukes J, Mauricio IL, Schonian G, Dujardin JC, Soteriadou K, Dedet JP, et al. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc Natl Acad Sci U S A (2007) 104:9375-80. doi:10.1073/pnas.0703678104
6. Lodge R, Diallo TO, Descoteaux A. Leishmania donovani lipophosphoglycan blocks NADPH oxidase assembly at the phagosome membrane. Cell Microbiol (2006) 8:1922-31. doi:10.1111/j.1462-5822.2006.00758.x
7. Kedzierski L. Leishmaniasis vaccine: where are we today? J Glob Infect Dis (2010) 2(2):177-85. doi:10.4103/0974-777X.62881
8. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 19:111-26. doi:10.1128/CMR.19.1.111-126.2006
9. Mutiso JM, Macharia JC, Kiio MN, Ichagichu JM, Rikoi H, Gicheru MM. Development of Leishmania vaccines: predicting the future from past and present experience. J Biomed Res (2013) 27(2):85-102. doi:10.7555/JBR.27.20120064
10. Kamhawi S, Oliveira F, Valenzuela JG. Using humans to make a human leishmaniasis vaccine. Sci Transl Med (2014) 6:234fs18. doi:10.1126/scitranslmed.3009118
11. Kharazmi A, Kemp K, Ismail A, Gasim S, Gaafar A, Kurtzhals JA, et al. T-cell response in human leishmaniasis. Immunol Lett (1999) 65:105-8. doi:10.1016/S0165-2478(98)00132-1
12. Stager S, Smith DF, Kaye PM. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis. J Immunol (2000) 165:7064-71. doi:10.4049/jimmunol.165.12.7064
13. Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics Clin Appl (2008) 3:372-86. doi:10.1002/prca.200780017
14. Lundegaard C, Lund O, Kesmir C, Brunak S, Nielsen M. Modeling the adaptive immune system: predictions and simulations. Bioinformatics (2007) 23(24):3265-75. doi:10.1093/bioinformatics/btm471
15. Palatnik de Sousa CB. Vaccines for leishmaniasis in the fore coming 25 years. Vaccine (2008) 26:1709-24. doi:10.1016/j.vaccine.2008.01.023
16. Bray RS, Modabber F. The history of leishmaniasis. In: Gilles HM, editor. Protozoal Diseases. New York, NY: Hodder Arnold Publisher (2000). p. 414-9.
17. Handman E. Leishmaniasis: current status of vaccine development. Clin Microbiol Rev (2001) 14:229-43. doi:10.1128/CMR.14.2.229-243.2001
18. Pessoa SB. Segunda nota sobre a vacinacao preventiva na leishmaniose tegumentar Americana com leptomones mortas. Rev Paul Med (1941) 19:106.
19. Pessoa SB, Pestana BR. Enseaio sobre vacinacao preventive na leishmaniose tegumentar americana com germenes mortos. Arq Hig Saude Publ (1941) 6:141-7.
20. Basyoni MM. Leishmania vaccines updates. PUJ (2012) 5(1):1-10.
21. Zijlstra EE, El-Hassan AM, Ismael A, Ghalib HW. Endemic kala-azar in eastern Sudan: a longitudinal study on the incidence of clinical and subclinical infection and post-kala-azar dermal leishmaniasis. Am J Trop Med Hyg (1994) 51:826-36.
22. Dube A, Sharma P, Srivastava JK, Misra A, Naik S, Katiyar JC. Vaccination of langur monkeys (Presbytis entellus) against Leishmania donovani with autoclaved L. major plus BCG. Parasitology (1998) 116:219-21. doi:10.1017/S0031182097002175
23. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, et al. Successful vaccination against Leishmania donovani infection in Indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine (2001) 19:3485-92. doi:10.1016/S0264-410X(01)00058-5
24. Khalil EA, El-Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmainiasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet (2000) 356:1565-9. doi:10.1016/S0140-6736(00)03128-7
25. Kamil AA, Khalil EA, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, et al. Alum-precipitated autoclaved Leishmania major plus Bacillus Calmette-Guerrin, a candidate vaccine for visceral leishmaniasis: safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg (2003) 97(3):365-8. doi:10.1016/S0035-9203(03)90171-4
26. Mohebali M, Khamesipour A, Mobedi I, Zarei Z, Hashemi-Fesharki R. Double blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I. R. Iran. Vaccine (2004) 22:4097-100. doi:10.1016/j.vaccine.2004.03.058
27. Musa AM, Khalil EA, Mahgoub FA, Elgawi SH, Modabber F, Elkadaru AE, et al. Immunochemotherapy of persistent post-kala-azar dermal leishmaniasis: a novel approach to treatment. Trans R Soc Trop Med Hyg (2008) 102:58-63. doi:10.1016/j.trstmh.2007.08.006
28. De Luca PM, Mayrink W, Alves CR, Coutinho SG, Oliveira MP, Bertho AL, et al. Evaluation of the stability and immunogenicity of autoclaved and nonautoclaved preparations of a vaccine against American tegumentary leishmaniasis. Vaccine (1999) 17:1179-85. doi:10.1016/S0264-410X(98)00338-7
29. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun (2005) 73:6372-82. doi:10.1128/IAI.73.10.6372-6382.2005
30. Papadopoulou B, Roy G, Breton M, Kundig C, Dumas C, Fillion I, et al. Reduced Infectivity of a Leishmania donovani biopterin transporter genetic mutant and its use as an attenuated strain for vaccination. Infect Immun (2002) 70:62-8. doi:10.1128/IAI.70.1.62-68.2002
31. Silvestre R, Cordeiro-da-Silva A, Santarém N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient Leishmania infantum induces a defined IFN-?/IL-10 pattern that correlates with protection. J Immunol (2007) 179:3161-70. doi:10.4049/jimmunol.179.5.3161
32. Mizbani A, Taheri T, Zahedifard F, Taslimi Y, Azizi H, Azadmanesh K, et al. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis. Vaccine (2009) 28:53-62. doi:10.1016/j.vaccine.2009.09.114
33. Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, et al. Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice. J Immunol (2013) 190(5):2138-49. doi:10.4049/jimmunol.1202801
34. Kumari S, Samant M, Khare P, Misra P, Dutta S, Kolli BK, et al. Photodynamic vaccination of hamsters with inducible suicidal mutants of Leishmania amazonensis elicits immunity against visceral leishmaniasis. Eur J Immunol (2009) 39:178-91. doi:10.1002/eji.200838389
35. Selvapandiyan A, Dey R, Nylen R, Duncan R, Sacks D, Nakasi HL. Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. J Immunol (2009) 183:1813-20. doi:10.4049/jimmunol.0900276
36. Fiuza JA, Santiago HC, Selvapandiyan A, Gannavaram S, Ricci ND, Bueno LL, et al. Induction of immunogenicity by live attenuated Leishmania donovani centrin deleted parasites in dogs. Vaccine (2013) 31:1785-92. doi:10.1016/j.vaccine.2013.01.048
37. Mutiso JM, Macharia JC, Taracha E, Gicheru MM. Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops). J Biomed Res (2012) 26:8-16. doi:10.1016/S1674-8301(12)60002-5
38. Jaffe CL, Rachamim N, Sarfstein R. Characterization of two proteins from Leishmania donovani and their use for vaccination against visceral leishmaniasis. J Immunol (1990) 144:699-706.
39. Palatnik de Sousa CB, Paraguai de Souza E, Gomes EM, Borojevic R. Experimental murine Leishmania donovani infection: immunoprotection by the fucose-mannose ligand (FML). Braz J Med Biol Res (1994) 27:547-55.
40. Palatnik de Sousa CB, Moreno MB, Paraguai de Souza E, Borojevic R. The FML-vaccine (fucose-mannose ligand) protects hamsters from experimental kala-azar. J Braz Assoc Adv Sci (1994) 46:290-6.
41. Santos WR, Paraguai de Souza E, Palatnik M, Palatnik de Sousa CB. Vaccination of Swiss albino mice against experimental visceral leishmaniasis with the FML antigen of Leishmania donovani. Vaccine (1999) 17:2554-61. doi:10.1016/S0264-410X(99)00058-4
42. Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, et al. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine. Vaccine (2006) 24:2423-31. doi:10.1016/j.vaccine.2005.11.061
43. Lemesre JL, Holzmuller P, Cavaleyra M, Goncalves RB, Hottin G, Papierok G. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes. Vaccine (2005) 23:2825-40. doi:10.1016/j.vaccine.2004.11.061
44. Bourdoiseau G, Hugnet C, Goncalves RB. Effective humoral and cellular immunoprotective responses in LiESAp-MDP vaccinated protected dogs. Vet Immunol Immunopathol (2009) 128:71-8. doi:10.1016/j.vetimm.2008.10.309
45. Wilson ME, Young BM, Andersen KP, Weinstock JV, Metwali A, Ali KM, et al. A recombinant Leishmania chagasi antigen that stimulates cellular immune responses in infected mice. Infect Immun (1995) 63:2062-9.
46. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, et al. Protective immunity against challenge with Leishmania chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine (2008) 26:5888-95. doi:10.1016/j.vaccine.2008.05.095
47. Bhardwaj S, Vasishta RK, Arora SK. Vaccination with a novel recombinant Leishmania antigen plus MPL provides partial protection against L. donovani challenge in experimental model of visceral leishmaniasis. Exp Parasitol (2009) 121:29-37. doi:10.1016/j.exppara.2008.09.019
48. Kushawaha PK, Gupta R, Sundar S, Sahasrabuddhe AA, Dube A. Elongation factor-2, a Th1 stimulatory protein of Leishmania donovani, generates strong IFN-? and IL-12 response in cured Leishmania-infected patients/hamsters and protects hamsters against Leishmania challenge. J Immunol (2011) 187:6417-27. doi:10.4049/jimmunol.1102081
49. Gupta R, Kushawaha PK, Tripathi CD, Sundar S, Dube A. A novel recombinant Leishmania donovani p45, a partial coding region of methionine aminopeptidase, generates protective immunity by inducing a Th1 stimulatory response against experimental visceral leishmaniasis. Int J Parasitol (2012) 42(5):429-35. doi:10.1016/j.ijpara.2012.02.013
50. Kushawaha PK, Gupta R, Tripathi CD, Khare P, Jaiswal AK, Sundar S, et al. Leishmania donovani triose phosphate isomerase: a potential vaccine target against visceral leishmaniasis. PLoS One (2012) 7:e45766. doi:10.1371/journal.pone.0045766
51. Kushawaha PK, Gupta R, Tripathi CD, Sundar S, Dube A. Evaluation of Leishmania donovani protein disulfide isomerase as a potential immunogenic protein/vaccine candidate against visceral leishmaniasis. PLoS One (2012) 7:e35670. doi:10.1371/journal.pone.0035670
52. Khare P, Jaiswal AK, Tripathi CD, Joshi S, Sundar S, Dube A. Efficacy of Leishmania donovani trypanothione reductase,identified as a potent Th1 stimulatory protein, for its immunogenicity and prophylactic potential against experimental visceral leishmaniasis. Parasitol Res (2014) 113:851-62. doi:10.1007/s00436-013-3716-5
53. Gupta R, Kumar V, Kushawaha PK, Tripathi CP, Joshi S, Sahasrabuddhe AA, et al. Characterization of glycolytic enzymes - rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis. PLoS One (2014) 9(1):e86073. doi:10.1371/journal.pone.0086073
54. Chavez-Fumagalli MA, Costa MA, Oliveira DM, Ramirez L, Costa LE, Duarte MC, et al. Vaccination with the Leishmania infantum ribosomal proteins induces protection in BALB/c mice against Leishmania chagasi and Leishmania amazonensis challenge. Microbes Infect (2010) 12:967-77. doi:10.1016/j.micinf.2010.06.008
55. Martins VT, Chavez-Fumagalli MA, Costa LE, Canavac AM, Lage PS, Duarte MC, et al. Antigenicity and protective efficacy of a Leishmania amastigote specific protein, member of the super-oxygenase family, against visceral leishmaniasis. PLoS Negl Trop Dis (2013) 7(3):e2148. doi:10.1371/journal.pntd.0002148
56. Choudhury R, Das P, Bhaumik SK, De T, Chakraborti T. In situ immunolocalization and stage-dependent expression of a secretory serine protease in Leishmania donovani and its role as a vaccine candidate. Clin Vaccine Immunol (2010) 17:660-7. doi:10.1128/CVI.00358-09
57. Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, et al. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial. Vaccine (2007) 25:4223-34. doi:10.1016/j.vaccine.2007.02.083
58. Molano I, Garcia Alonso M, Miron C. A Leishmania infantum multi-component antigenic protein mixed with live BCG confers protection to dogs experimentally infected with L. infantum. Vet Immunol Immunopathol (2003) 92:1-13. doi:10.1016/S0165-2427(02)00315-X
59. Parody N, Soto M, Requena JM, Lonso CA. Adjuvant guided polarization of the immune humoral response against a protective multicomponent antigenic protein (Q) from Leishmania infantum. A CpG +Q mix protects Balb/c mice from infection. Parasite Immunol (2004) 26:283-93. doi:10.1111/j.0141-9838.2004.00711.x
60. Gradoni L, Foglia Manzillo V, Pagano A, Piantedosi D, De Luna R, Gramiccia M, et al. Failure of a multi-subunit recombinant Leishmania vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine (2005) 23:5245-51. doi:10.1016/j.vaccine.2005.07.001
61. Coler RN, Yasuyuki G, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect Immun (2007) 75:4648-54. doi:10.1128/IAI.00394-07
62. Trigo J, Abbehusen M, Netto EM, Nakatani M, Pedral-Sampaio G, de Jesus RS. Treatment of canine visceral leishmaniasis by the vaccine Leish-111f +MPL-SE. Vaccine (2010) 28:3333-40. doi:10.1016/j.vaccine.2010.02.089
63. Bertholet S, Goto Y, Carter L. Optimized subunit vaccine protects against experimental leishmaniasis. Vaccine (2009) 23:7036-45. doi:10.1016/j.vaccine.2009.09.066
64. Goto Y, Bhatia A, Raman VS, Liang H, Mohamath R, Picone AF, et al. KSAC, the first defined polyprotein vaccine candidate for visceral leishmaniasis. Clin Vaccine Immunol (2011) 18:1118-24. doi:10.1128/CVI.05024-11
65. Ghosh A, Zhang WW, Matlashewski G. Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections. Vaccine (2001) 20:59-66. doi:10.1016/S0264-410X(01)00322-X
66. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36 (LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun (2001) 69:4719-25. doi:10.1128/IAI.69.8.4719-4725.2001
67. Sukumaran B, Tewary P, Saxena S, Madhubala R. Vaccination with DNA encoding ORFF antigen confers protective immunity in mice infected with Leishmania donovani. Vaccine (2003) 21:1292-9. doi:10.1016/S0264-410X(02)00352-3
68. Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial sensitive and resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol (2005) 174:7160-71. doi:10.4049/jimmunol.174.11.7160
69. Bhaumik S, Basu R, Sen S, Naskar K, Roy S. KMP-11 DNA immunization significantly protects against L. donovani infection but requires exogenous IL-12 as an adjuvant for comparable protection against L. major. Vaccine (2009) 27:1306-16. doi:10.1016/j.vaccine.2008.12.053
70. Saldarriaga OA, Travi BL, Park W, Perez LE, Melby PC. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs. Vaccine (2006) 24:1928-40. doi:10.1016/j.vaccine.2005.10.052
71. Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, Mullen AB, et al. DNA vaccination against the parasite enzyme gamma glutamyl cysteine synthetase confers protection against Leishmania donovani infection. Vaccine (2007) 25:4502-9. doi:10.1016/j.vaccine.2007.03.014
72. Sharma A, Madhubala R. Ubiquitin conjugation of open reading frame F DNA vaccine leads to enhanced cell-mediated immune response and induces protection against both antimony-susceptible and -resistant strains of Leishmania donovani. J Immunol (2009) 183:7719-31. doi:10.4049/jimmunol.0900132
73. Samant M, Gupta R, Kumari S, Misra P, Khare P, Kushawaha PK, et al. Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis. J Immunol (2009) 183:470-9. doi:10.4049/jimmunol.0900265
74. Guha R, Gupta D, Rastogi R, Vikram R, Krishnmurthy G, Bimal S, et al. Vaccination with Leishmania hemoglobin receptor-encoding DNA protects against visceral leishmaniasis. Sci Transl Med (2013) 5(202):202ra121. doi:10.1126/scitranslmed.3006406
75. Marques-da-Silva EA, Coelho EA, Gomes DC, Vilela MC, Masioli CZ, Tavares CA, et al. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-? production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol Res (2005) 98(1):67-74. doi:10.1007/s00436-005-0008-8
76. Fragaki K, Suffia I, Ferrua B, Rousseau D, Le Fichoux Y, Kubar J. Immunisation with DNA encoding Leishmania infantum protein papLe22 decreases the frequency of parasitemic episodes in infected hamsters. Vaccine (2001) 19:1701-9. doi:10.1016/S0264-410X(00)00398-4
77. Gomes DC, Pinto EF, de Melo LD, Lima WP, Larraga V, Lopes UG, et al. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine (2007) 25(12):2168-72. doi:10.1016/j.vaccine.2006.11.060
78. Carrion J, Folgueira C, Alonso C. Immunization strategies against visceral leishmaniasis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine (2008) 26:2537-44. doi:10.1016/j.vaccine.2008.03.003
79. Aguilar-Be I, da Silva Zardo R, Paraguai de Souza E, Borja-Cabrera GP, Rosado-Vallado M, Mut-Martin M, et al. Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis. Infect Immun (2005) 73(2):812-9. doi:10.1128/IAI.73.2.812-819.2005
80. Gamboa-Leon R, Paraguaide Souza E, Borja-Cabrera GP, Santos FN, Myashiro LM, Pinheiro RO, et al. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase DNA vaccine of Leishmania donovani. Vaccine (2006) 24:4863-73. doi:10.1016/j.vaccine.2006.03.005
81. Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Costa MM, Rezende SA, et al. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect (2007) 9:1070-7. doi:10.1016/j.micinf.2007.05.012
82. Tewary P, Jain M, Sahani MH, Saxena S, Madhubala R. A heterologous prime-boost vaccination regimen using ORFF DNA and recombinant ORFF protein confers protective immunity against experimental visceral leishmaniasis. J Infect Dis (2005) 191:2130-7. doi:10.1086/430348
83. Mazumder S, Maji M, Das A, Ali N. Potency, efficacy and durability of DNA/DNA, DNA/protein and protein/protein based vaccination using GP63 against Leishmania donovani in BALB/c mice. PLoS One (2011) 6:e14644. doi:10.1371/journal.pone.0014644
84. Dondji B, Perez-Jimenez E, Goldsmith-Pestana K, Esteban M, McMahon-Pratt D. Heterologous prime - boost vaccination with the LACK antigen protects against murine visceral leishmaniasis. Infect Immun (2005) 73:5286-9. doi:10.1128/IAI.73.8.5286-5289.2005
85. Ramiro MJ, Zarate JJ, Hanke T, Rodriguez D, Rodriguez JR, Esteban M, et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime-boost regime using DNA vaccine and vaccinia recombinant vectors expressing LACK. Vaccine (2003) 21:2474-84. doi:10.1016/S0264-410X(03)00032-X
86. Rafati S, Zahedifard F, Nazgouee F. Prime boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine (2006) 24:2169-75. doi:10.1016/j.vaccine.2005.11.011
87. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine (2005) 23(28):3716-25. doi:10.1016/j.vaccine.2005.02.009
88. Afrin F, Rajesh R, Anam K, Gopinath M, Pal S, Ali N. Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice. Infect Immun (2002) 70:6697-706. doi:10.1128/IAI.70.12.6697-6706.2002
89. Mazumder S, Ravindran R, Banerjee A, Ali N. Non-coding pDNA bearing immunostimulatory sequences co-entrapped with Leishmania antigens in cationic liposomes elicits almost complete protection against experimental visceral leishmaniasis in BALB/c mice. Vaccine (2007) 25:8771-81. doi:10.1016/j.vaccine.2007.10.028
90. Bhowmick S, Ravindran R, Ali N. GP63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun (2008) 76:1003-15. doi:10.1128/IAI.00611-07
91. Agallou M, Smirlis D, Soteriadou KP, Karagouni E. Vaccination with Leishmania histone H1-pulsed dendritic cells confers protection in murine visceral leishmaniasis. Vaccine (2012) 30:5086-93. doi:10.1016/j.vaccine.2012.05.075
92. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sandfly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci U S A (2008) 105:7845-50. doi:10.1073/pnas.0712153105
93. Collin N, Gomes R, Teixeira C, Cheng L, Laughinghouse A, Ward JM, et al. Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania. PLoS Pathog (2009) 5(5):e1000441. doi:10.1371/journal.ppat.1000441
94. Reis AB, Giunchetti RC, Carrillo E, Martins-Filho OA, Moreno J. Immunity to Leishmania and the rational search for vaccines against canine leishmaniasis. Trends Parasitol (2010) 26(7):341-9. doi:10.1016/j.pt.2010.04.005
95. Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol (2005) 21:244-9. doi:10.1016/j.pt.2005.03.006
96. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun (2001) 69:4103-8. doi:10.1128/IAI.69.6.4103-4108.2001
97. Noazin S, Modabber F, Khamesipour A, Smith PG, Moulton LH, Nasseri K, et al. First generation leishmaniasis vaccines: a review of field efficacy trials. Vaccine (2008) 26:6759-67. doi:10.1016/j.vaccine.2008.09.085
98. Kaye P, Scott P. Leishmaniasis: complexity at the host pathogen interface. Nat Rev Microbiol (2011) 9:604-15. doi:10.1038/nrmicro2608
99. Kumar R, Engwerda C. Vaccines to prevent leishmaniasis. Clin Trans Immunol (2014) 3:e13. doi:10.1038/cti.2014.4
100. Kumari S, Samant M, Khare P, Sundar S, Sinha S, Dube A. Induction of Th1-type cellular responses in cured/exposed Leishmania-infected patients and hamsters against polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa. Vaccine (2008) 26:4813-8. doi:10.1016/j.vaccine.2008.06.102
101. Kumari S, Samant M, Misra P, Khare P, Sisodia B, Shasany AK, et al. Th1-stimulatory polyproteins of soluble Leishmania donovani promastigotes ranging from 89.9 to 97.1kDa offers long-lasting protection against experimental visceral leishmaniasis. Vaccine (2008) 26:5700-11. doi:10.1016/j.vaccine.2008.08.021
102. Vedvick TS, Carter L, Garner M, Goto Y, Bertholet S, Reed SG, et al. An improved manufacturing process for a recombinant polyprotein vaccine. Biopharm Inter (2008) January(Supplement):14-22.
103. Das S, Freier A, Boussoffara T, Das S, Oswald D, Losch FO, et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med (2014) 6:234ra56. doi:10.1126/scitranslmed.3008222
104. Bhowmick S, Mazumdar T, Sinha R, Ali N. Comparison of liposome based antigen delivery systems for protection against Leishmania donovani. J Control Release (2010) 141:199-207. doi:10.1016/j.jconrel.2009.09.018
105. Valenzuela JG, Belkaid Y, Garfield MK, Mendez S, Kamhawi S, Rowton ED, et al. Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J Exp Med (2001) 194(3):331-42. doi:10.1084/jem.194.3.331
106. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol (2001) 167:5226-30. doi:10.4049/jimmunol.167.9.5226
107. Duthie MS, Reed SG. The emergence of defined subunit vaccines for the prevention of leishmaniasis. Curr Trop Med Rep (2014) 1(3):154-62. doi:10.1007/s40475-014-0024-9
108. Silvestre R, Cordeiro-da-Silva A, Ouaissi A. Live attenuated Leishmania vaccines: a potential strategic alternative. Arch Immunol Ther Exp (Warsz) (2008) 56(2):123-6. doi:10.1007/s00005-008-0010-9
109. Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat Immunol (2005) 6:163-70. doi:10.1038/ni1162
110. Foulds KE, Wu CY, Seder RA. Th1 memory: implications for vaccine development. Immunol Rev (2006) 211:58-66. doi:10.1111/j.0105-2896.2006.00400.x
111. Titus RG, Gueiros-Filho FJ, De Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc Natl Acad Sci U S A (1995) 92(22):10267-71. doi:10.1073/pnas.92.22.10267
112. Selvapandiyan A, Debrabant A, Duncan R. Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania. J Bio Chem (2004) 279(24):25703-10. doi:10.1074/jbc.M402794200
113. Nardin E. The past decade in malaria synthetic peptide vaccine clinical trials. Hum Vaccin (2010) 6(1):27-38. doi:10.4161/hv.6.1.9601
114. Wang Y, Wang G, Zhang D, Yin H, Wang M. Screening and identification of novel B cell epitopes of Toxoplasma gondii SAG1. Parasit Vectors (2013) 6:125. doi:10.1186/1756-3305-6-125
115. Serna C, Lara JA, Rodrigues SP, Marques AF, Almeida IC, Maldonado RA. A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease. Vaccine (2014) 32:3525-32. doi:10.1016/j.vaccine.2014.04.026
116. Jardim A, Alexander J, Teh HS, Ou D, Olafson RW. Immunoprotective Leishmania major synthetic T-cell epitopes. J Exp Med (1990) 172:645-8. doi:10.1084/jem.172.2.645
117. Yang DM, Rogers MV, Liew FY. Identification and characterization of host-protective T-cell epitopes of a major surface glycoprotein (GP63) from Leishmania major. J Immunol (1991) 72:3-9.
118. Frankenburg S, Axelrod O, Kutner S, Greenblatt CL, Klaus SN, Pirak EA, et al. Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine. Vaccine (1996) 14(9):923-9. doi:10.1016/0264-410X(95)00245-V
119. Spitzer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine (1999) 17:1298-300. doi:10.1016/S0264-410X(98)00363-6
120. Rezvan H. Immunogenicity of HLA-DR1 restricted peptides derived from Leishmania major GP63 using FVB/N-DR1 transgenic mouse model. Iran J Parasitol (2013) 8(2):273-9.
121. Rezvan H, Rees R, Ali SA. Immunogenicity of MHC class I peptides derived from Leishmania mexicana GP63 in HLA-A2.1 transgenic (HHDII) and BALB/C mouse models. Iran J Parasitol (2012) 7(4):27-40.
122. Elfaki ME, Khalil EA, Groot AS, Musa AM, Gutierrez A, Younis BM, et al. Immunogenicity and immune modulatory effects of in silico predicted L. donovani candidate peptide vaccines. Hum Vaccin Immunother (2012) 8(12):1769-74. doi:10.4161/hv.21881
123. Basu R, Roy S, Walden P. HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis (2007) 195:1373-80. doi:10.1086/513439
124. Resende DM, Caetano BC, Dutra MS, Penido ML, Abrantes CF, Verly RM, et al. Epitope mapping and protective immunity elicited by adenovirus expressing the Leishmania amastigote specific A2 antigen: correlation with IFN-? and cytolytic activity by CD8+ T cells. Vaccine (2008) 26:4585-93. doi:10.1016/j.vaccine.2008.05.091
125. Seyed N, Zahedifard F, Safaiyan S, Gholami E, Doustdari F, Azadmanesh K, et al. In silico analysis of six known Leishmania major antigens and in vitro evaluation of specific epitopes eliciting HLA-A2 restricted CD8 T cell response. PLoS Negl Trop Dis (2011) 5(9):e1295. doi:10.1371/journal.pntd.0001295
126. Matos DC, Faccioli LA, Cysne-Finkelstein L, Luca PM, Corte-Real S, Armoa GR, et al. Kinetoplastid membrane protein-11 is present in promastigotes and amastigotes of Leishmania amazonensis and its surface expression increases during metacyclogenesis. Mem Inst Oswaldo Cruz (2010) 105:341-7. doi:10.1590/S0074-02762010000300018
127. Charest H, Matlashewski G. Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene. Mol Cell Biol (1994) 14:2975-84.
128. Agallou M, Athanasiou E, Koutsoni O, Dotsika E, Karagouni E. Experimental validation of multi-epitope peptides including promising MHC class I- and II-restricted epitopes of four known Leishmania infantum proteins. Front Immunol (2014) 5:268. doi:10.3389/fimmu.2014.00268